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Neurocysticercosis, the infection caused by the larval form of the tapeworm Taenia solium, is the most common parasitic disease
of the central nervous system and the most common cause of acquired epilepsy worldwide. This has primarily been a disease
that remains endemic in low-socioeconomic countries, but because of increased migration neurocysticercosis is being diagnosed
more frequently in high-income countries. During the past three decades improved diagnostics, imaging, and treatment have led
to more accurate diagnosis and improved prognosis for patients. This article reviews the current literature on neurocysticercosis,
including newer diagnostics and treatment developments.
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1.Introduction
Neurocysticercosis (NCC) is a neurologic infection caused
by the larval stage of the tapeworm Taenia solium. In the
developing world, NCC, infection of the central nervous
system (CNS) with the T. solium larvae, is the most common
cause of acquired epilepsy [1–3]. Because of globalization,
many clinicians in industrialized countries who are unfa-
miliar with NCC are now faced with managing this disease.
Humans are the deﬁnitive hosts for this parasite, and swine
are the intermediate hosts. The adult tapeworm develops in
human hosts after they ingest live cysticercus in undercook
pork. NCC develops when humans accidentally ingest eggs.
This occurs when feces of human carriers contaminates
food, although the most important risk factor for the
acquisition of cysticercosis is the proximity of a tapeworm
carrier [4, 5]. Adult tapeworms shed proglottids, and each
proglottid contains approximately 1000 to 2000 eggs. Once
the hexacanth embryo reaches the parenchyma it forms
cysticerci which undergo four stages of involution [6].
The ﬁrst is the vesicular stage characterized by a cyst
with a translucent vesicular wall, transparent ﬂuid, and a
viable invaginated scolex. During this stage there is little
host inﬂammatory reaction. The cyst then develops a thick
vesicular wall, the ﬂuid becomes turbid, and the scolex
degenerates during the next stage, which is termed the
colloidal stage. An intense inﬂammatory host response
is seen and is reﬂected in the pathology which reveals
varying degrees of acute and chronic inﬂammation [1, 6].
Radiographic examination reveals cystic lesions with edema
and enhancement and seizures are common [7]. The cyst
continues to degenerate as it moves into the granular stage
which is characterized by a thick vesicular wall, degenerated
scolex, gliosis, and little inﬂammatory host response. Ulti-
mately the parasite transforms into coarse calciﬁed nodules;
the calciﬁc stage [1, 2, 6].
2. ClinicalManifestationsof
Neurocysticercosis(NCC)
The clinical manifestations of NCC range from asymp-
tomatic to life threatening. Within the CNS it can aﬀect
the parenchyma, subarachnoid space, or intraventricular
system.Ocularandspinaldiseaseoccurs,butislesscommon.
Therefore, the clinical manifestations are pleomorphic and
dependant on the location, number, and stage of the cysts
at presentation. NCC is the leading cause of adult-onset2 Interdisciplinary Perspectives on Infectious Diseases
epilepsyinareasoftheworldwhereitisendemic,particularly
in Latin America, Asia, and Africa [1]. Seizures are com-
monly generalized tonic-clonic or simple partial. Epilepsy
occurs more frequent in patients with parenchymal disease,
although it can occur in patients with cysts in the cortical
sulci [1]. Seizures due to cysticercosis usually occur when
the dying cyst incites an inﬂammatory reaction, but has been
reported in the cystic stage. For many patients epilepsy may
be the sole presentation of the disease with 50%–70% of
patients experiencing recurrent seizures [8, 9].
There are multiple ways that cysticercosis can cause
seizures. As noted, seizures can occur early in the disease
in the setting of intense inﬂammation associated with
viable or degenerating cysts. They can also occur secondary
to vasculitis and infarction which occurs in the setting
of subarachnoid disease [10]. Lastly, increasing evidence
implicates calciﬁed NCC in the development and mainte-
nance of seizures and epilepsy [11]. Patients who present
with seizures in regions where infection with T. solium is
endemic commonly have calciﬁed brain lesions observed on
computerized axial tomography (CT) scan that are typical
for NCC. In population-based studies calciﬁed lesions on
CT are much more common than viable cysts, and they
are more prevalent in patients with epilepsy than they are
in asymptomatic patients [11–13]. Strong evidence supports
the role of calciﬁed lesions in seizures; there is a high
prevalence of cerebral calciﬁcations in patients with seizures
in the absence of other etiologies, and there is a positive
correlation between endemic populations with increased
proportions of calciﬁcation and seizure activity. In addition,
individuals with calciﬁed granulomas have increased risk of
ongoing seizure [14–17].
There has been increasing evidence that perilesional
edema, which occurs episodically, is associated with seizures
[14, 15, 18–20]. Perilesional edema appears as a bright
signal using magnetic resonance imaging (MRI) FLAIR or
T2 imaging (Figure 1). It is almost always accompanied by
enhancement around the calciﬁed focus [11]. Previously
calciﬁed NCC has been classiﬁed as the inactive form of
the disease, suggesting that it is less important than other
forms of NCC [21]. Recently a growing literature is ﬁnding
that perilesional edema related to calciﬁcations seems to be a
relatively frequent phenomenon, with reports ranging from
23%–35% in literature [8, 14, 22]. The natural history or
pathophysiology of perilesional edema is not yet known,
but it appears that it recurs, and repeated episodes tend
to be associated with the same lesions in a patient. In a
recent prospective nested case-control study, 110 patients
with seizures or headaches and calciﬁed lesions in an
endemic region were followed for recurrent seizures. Of
those with recurrent seizures, perilesional edema was noted
on MRI in 50% as opposed to 9% of asymptomatic matched
controls [23]. This study suggests that perilesional edema is
a common and potentially preventable cause of seizure in
endemic regions.
Although, seizures are the most common clinical man-
ifestation of parenchymal NCC, focal neurologic signs have
been reported and are usually related to the number,
size, and location of the parasites in individuals with
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Figure 1: (a) Baseline CT scan demonstrating a dense calciﬁcation
in the left frontal lobe as well as other calciﬁcations. (b) MRI images
that used ﬂuid attenuated recovery after the patient had a seizure
revealing perilesional edema.
parenchymal disease. Intracranial hypertension can occur in
patients with parenchymal NCC and is termed cysticercotic
encephalitis [1, 24, 25]. This manifestation has been best
described in children and young woman and is a result
of the acute inﬂammatory response to massive cysticercal
infection resulting in brain edema. Patients present with
a syndrome characterized by clouding of consciousness,
seizures, decreased visual acuity, headache, vomiting, and
papilledema which can be subacute or acute in onset [1, 22].
These patients are treated with mannitol and corticosteroids
in an attempt to control the inﬂammation and intracranial
hypertension. Patients may even require decompressive
temporal craniotomy. Those individuals with this form of
NCC would not be candidates for antiparasitic agents, since
treatment could exacerbate the inﬂammation and edema.
Other causes of intracranial hypertension in patients with
parenchymal NCC include the development of a large cyst
that displaces midline structures or obstructs the ﬂow of
cerebrospinal ﬂuid (CSF) in the cerebral aqueduct.
Psychiatric manifestations of NCC, such as depression
and psychosis, have been described [26, 27]. A recent
study found that patients admitted to a chronic inpatient
psychiatric unit were more likely to have a positive serology
for T. solium then healthy controls in the community. Of
theseinpatients,thosewithmentalretardationwerefoundto
carry an increase risk of cysticercosis compared with patients
with other psychiatric disorders. These patients were not
carryingadultTaenia spp.intheirstoolanddidnothaveCNS
imaging, but the high prevalence of a positive cysticercosis
serologyintheinpatientpsychiatricgroupsuggeststhatthere
is a large proportion of cysticercosis in this group of patients
[28]. Further studies are needed to explore the relationship
between NCC and psychiatric disease.
Subarachnoid NCC is a common ﬁnding at autopsy,
but when cysticerci ﬁnd their way to the Sylvian ﬁssure
or the basilar cisterns the result can be devastating for the
patient. The cysticercus larva (after embedding itself in the
parenchyma) undergoes four stages of evolution: vesicular,
vesicular colloid, granular nodular, and nodular calciﬁedInterdisciplinary Perspectives on Infectious Diseases 3
[1]. This evolution does not occur in the intraventricular
or the subarachnoid form of NCC. The cisternal NCC is
also-called the racemose type of cysticerosis. Racemose NCC
refers to “aberrant proliferating cestode larvae” that manifest
as solitary or multiple unencapsulated bladders that bud
exogenously to form a multilocular cyst resembling a bunch
of grapes [29]. The multiple cysts of the racemose type
occur in nonconﬁning areas in and around the brain such
as the suprasellar, sylvian and quadrigeminal cisterns. These
cysts are nonviable, degenerated interconnected bladders of
diﬀerent sizes that often lack scolices, and can reach large
sizes producing local mass eﬀect. Arachnoiditis can occur
with resulting communicating hydrocephalus secondary to
either chronic inﬂammation or ﬁbrosis of the arachnoid villi
causing obstruction to the reabsorption of CSF or extension
of the subarachnoid inﬂammatory reaction to the meninges
at the base of the brain occluding the forminal of Luschka
and Magendie [1, 30]. Cysticercotic arachnoiditis can lead to
entrapment of cranial nerves in the inﬂammatory exudates
that occur on the ventral aspect of the brain. Extraocular
muscle paralysis, diploplia and papillary abnormalities are
the result of entrapment of the ocular motor nerves. The
optic nerves and the optic chiasm can also be encased within
the exudates with subsequent development of decreased
visual acuity and visual ﬁeld defects [31, 32]. Acute aseptic
meningitis associated with subarachnoid disease has been
reported, but is rarely associated with fever and signs of
meningeal irritation [1].
Cerebrovascular complications of neurocysticercosis
include cerebral infarction, transient ischemic attacks and
brain hemorrhage [10, 33, 34]. The most common mecha-
nisms by which NCC produces cerebrovascular disease are
related to cerebral arteritis, mainly in those individuals with
subarachnoidcysticercosis.Earlierclinicalreportsofcerebral
infarction were secondary to small vessel involvement in
NCC. In a recent study that examined 28 patients with
subarachnoid disease 53% had angiographic evidence of
cerebral arteritis with the middle cerebral and posterior
cerebral arteries being the most commonly involved vessels
associated with clinical stroke syndrome. The frequency
of cerebral arteritis in subarachnoid cysticercosis seems to
be higher than previously reported, and middle-size vessel
involvement is a common ﬁnding [35].
Clinical manifestations of ventricular NCC vary accord-
ing to the size of the parasites, their location inside
the ventricular system, and the coexistence of granular
ependymitis [1, 36]. Lateral ventricles usually induce a
syndrome of increased intracranial pressure which may be
associated with focal neurological signs due to compression
of adjacent structures [37, 38]. Patients with third ventricle
cysticerci complain of progressively worsening headaches
and vomiting due to developing obstruction or may present
with sudden loss of conscious from acute hydrocephalus
[39, 40]. Paroxysmal headache and vomiting secondary to
intermittent obstruction at the level of the cerebral aqueduct
has been described [1]. Cysts in the fourth ventricle can
also cause subacute hydrocephalus that may be associated
with signs of brainstem dysfunction secondary to compres-
sion of the fourth ventricle [41]. A well-described clinical
presentation of fourth ventricle cyst is the Bruns’ syndrome
which is characterized by episodic headache, papilledema,
neck stiﬀness, sudden positional vertigo induced by rotatory
movements of the head, nausea and vomiting, drop attacks
and loss of consciousness with rapid recovery and long
asymptomatic periods [1]. Cysts in the third and fourth are
a well-described cause of sudden death due acute obstructive
hydrocephalus [41–43].
A degenerating cyst in the ventricles can result in an
inﬂammatory reaction throughout the ventricular system
leading to granular ependymitis. When this occurs the cyst
capsule can become ﬁxed to the ventricular wall with strong
adhesions and ﬁbrosis [41]. Increased intracranial pressure
due to hydrocephalus can occur if ependymitis occurs at the
level of the cerebral aqueduct. These patients tend to have
a more chronic course than those with cysts in the fourth
ventricle [44].
Spinal cord involvement in NCC is rare, accounting for
1%–5% of all cases [1, 45]. Spinal cord involvement can
be intramedullary or extramedullary with the latter being
more common. Intramedullary cysts are most common
in the thoracic spine and patients usually present with
gradual onset of myelopathy similar to the presentation
of intramedullary tumors [46–52]. Extramedullary cysts or
leptomeningealNCCisusuallyanextensionofsubarachnoid
disease which has migrated from the basilar cisterns. Cysts
may be single or may form clumps of multiple cysts
extendingalongtheentirespinalcanal[46,47].Theresulting
clinicalpictureischaracterizedbyacombinationofradicular
pain and motor deﬁcits of subacute onset and progressive
course [1].
Intraocular cysticerci may be located in the anterior
chamber, the lens, the vitreous and the subretinal space,
but the latter is the most common location. Cysts in the
subretinal space can cause progressive decrease in visual
acuity. Vitreous cysts can produce worsening vision with
the perception of something moving within the eye. Cysts
in the anterior chamber may induce a severe iridocyclitis,
whileretro-ocularintraorbitalcysticercimaycausedecreased
visual acuity due to pressure on the optic nerve [1, 53, 54].
3.Radiological Manifestations
Neuroimaging of parenchymal NCC depends on the stage
of the development of the parasites. In the vesicular stage
the cysticerci appear as cystic lesions within the brain
parenchyma [7]. CT and MRI reveal that the cyst wall
is thin and well demarcated from the parenchyma. The
cysts lack perilesional edema and do not enhance after
administration of contrast medium. There may be a bright
nodule in their interior giving the lesion a “hole with dot”
appearance that represents the scolex (Figure 2(a))[ 55].
As the cysts begin to degenerate they appear as ill-deﬁned
lesions surrounded by edema which enhance after contrast
medium administration. This is the colloidal stage of the cyst
and represents the so-called “acute encephalitic phase” of
NCC which likely represents an intense host reaction to the
parasite (Figure 2(b)). MRI reveals a thick and hypointense4 Interdisciplinary Perspectives on Infectious Diseases
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Figure 2: (a) MRI image revealing vesicular cysticerci (the central
dot represents the scolex). (b) Cyst beginning to degenerate with
perilesional edema and enhancement in the colloidal stage. (c) Cyst
in the granular stage without perilesional edema. (d) CAT scan
revealing multiple calciﬁcations in the calciﬁed stage.
wallwithmarkedperilesionaledema.Theperilesionaledema
is best visualized on MRI with the ﬂuid-attenuated inversion
recovery (FLAIR) technique [7]. Granular cysticerci appear
as nodular hyperdense lesions surrounded by edema or a rim
of gliosis aftercontrast medium administration (Figure 2(c))
[55].Calciﬁed(dead)cysticerciappearonCTassmallhyper-
dense nodules without perilesional edema (Figure 2(d))
or abnormal enhancement after contrast administration;
these lesions are usually not visualized by MRI. Conversely,
when calciﬁed lesions are associated with perilesional edema
and contrast enhancement, they are better seen by MRI
[7, 55].
Cysticerciwithinthebasilarcisternsareusuallymissedby
CTscanandrequireMRItoadequatelyvisualizethem.While
most subarachnoid cysts over the convexity of the cerebral
hemispheres are small, lesions located in the Sylvian ﬁssure
may reach 50mm or more in size; these parasites usually
have a mulitlobulated appearance, displace neighboring
structures, and behave as mass occupying lesions. Fibrous
arachnoiditis commonly occurs in subarachnoid disease
resulting in hydrocephalus which is the most common
CT ﬁnding in subarachnoid NCC [7, 46]. Leptomeningeal
enhancement at the base of the brain is observed best
by MRI [56]. In general, the neuroimaging appearance
of cerebrovascular complications is indistinguishable from
cerebral infarcts from other causes [10].
Ventricular cysts appear on CT images as cystic lesions.
They are initially isodense with the CSF and are therefore
not well visualized. However, their presence can be inferred
from distortions of the ventricular system causing asym-
metric or obstructive hydrocephalus [57]. In contrast, most
ventricular cysts are well visualized by MRI because their
signal properties diﬀer from those of the CSF, particularly
using FLAIR techniques [7]. They may also move within
the ventricular cavities in response to movements of the
patients’ head (ventricular migration sign), a phenomenon
that is best observed with MRI than with CT [58]. Occa-
sionally, this ﬁnding facilitates the diagnosis of ventricular
cysticercosis.
In patients with spinal NCC, CT may reveal symmetrical
enlargement of the cord (intramedullary cysts) or pseu-
doreticular formations within the spinal canal (leptomenin-
gal cysts). MRI reveals intramedullary cysticerci to be ring-
enhancing lesions that may have an eccentric hyperintense
nodule representing the scolex. Myelography still has a role
in the diagnosis of patients with spinal leptomeningeal
cysticercosis because it shows multiple ﬁlling defects in the
column of contrast material corresponding to each cyst
[59]. Leptomeningeal cysts may be mobile (changing their
position according to the movements of the patient) [7, 59,
60].
4.Serology
Only tests based on detection of antibodies speciﬁc for
T. solium antigens are reliable for clinical diagnosis and
epidemiologic studies. To date, these are limited to those
based on the use of puriﬁed glycoprotein antigens derived
from T. solium cysticerci. The current assay of choice is the
electroimmunotransfer blot (ETIB) using partially puriﬁed
antigenic extracts [61, 62]. This assay has a speciﬁcity
approaching 100% anda sensitivity of 94%–98% for patients
with two or more cystic or enhancing lesions. A major
limitation of these tests are frequent false negative results
in patients with single intracranial cysticerci, in which fewer
than 50% test positive. Sensitivity of speciﬁc antibody assays
is also relatively low in patients with only calciﬁed cysticerci
[63].
Detection of circulating parasite antigen reﬂects the
presence of live parasites establishes the presence of ongoing
viable infection and may permit quantitative veriﬁcation
of successful treatment [64–66]. Garcia and others have
used Ag-ELISA based on the use of a monoclonal antibody
(HP10) that reacts with a repetitive carbohydrate epitope
found in excretory/secretory and surface antigens of living
cysticerci [66, 67]. This assay had a sensitivity of 86% when
tested on (CSF) samples from a series of 50 Peruvian patients
with NCC [68]. The speciﬁcity of the assay is about 96%
and it has been used to follow patients after treatment.
Parasite antigen levels fell signiﬁcantly by 3 months after
treatment in patients with “cured” parenchymal disease
after albendazole therapy [66]. This study found that the
sensitivity is low in intraparenchymal NCC, especially in
patients with only a few intraparenchymal cysts [66]. InInterdisciplinary Perspectives on Infectious Diseases 5
a study examining patients with hydrocephalus and NCC
the assay was positive in 14 of 29 patients, but negative in
patients with calciﬁcations [69]. A drop in antigen levels
(serum and CSF) after treatment in subarachnoid disease
h a sb e e nr e p o r t e di nas m a l ln u m b e ro fp a t i e n t s[ 70].
The management of subarachnoid disease is particularly
complicated and the appropriate endpoint for treatment has
not been established. Further studies employing this assay
to follow patients with subarachnoid disease are needed.
Recently a monoclonal antibody-based ELISA to detect T.
solium antigens in urine has been described. The overall
sensitivity of urine antigen detection for viable parasites was
92%, which decreased to 62.5% in patients with a single cyst.
Most individuals with only calciﬁed cysticercosis were urine
antigen negative. This assay could be useful in diagnosis of
NCC and evaluating the eﬃcacy of treatment.
5. Treatment
5.1. Parenchymal Disease. Praziquantel and albendazole are
antiparasitic agents that are eﬀective against T. solium cys-
ticerci killing between 60% and 85% of parenchymal brain
cysticerci [71]. Most trials show greater cyst reduction with
albendazole administration. However, most of these studies
have been uncontrolled, observational imaging studies. The
majority of studies evaluated praziquantel at a dosage of
50mg/kg/d for 2 weeks, although studies describing a single
day regimen have also been described [8, 72–83]. Higher
doses have been used, but there is limited experience in
literature[71,72].Adoseof15mg/kgofalbendazoleforfour
weeks was initially employed, but later reduced to 15 days
and then to one week [74, 76, 80, 81, 83–88]. Between the
second and ﬁfth day of treatment with an antiparasitic agent
there may be an exacerbation of neurologic symptoms which
has been attributed to inﬂammation secondary to killing
of the cysticerci. Because of this inﬂammation steroids are
generally administered in conjunction with albendazole or
praziquanteltocontroltheresultingedema[71].Itshouldbe
noted that steroids decrease the plasma level of praziquantel,
but not albendazole [89].
Randomized studies evaluating the clinical beneﬁt of
treatment have yielded conﬂicting data with some studies
indicating a beneﬁt and others failing to show a diﬀerence
[90–94].Therehasbeenmuchcontroversywhethercysticidal
drugs modify the natural course of neurocysticercosis. In
2004 a randomized, placebo-controlled trial of treatment
of adults with 20 or less viable parenchymal cysts and
a history of seizures using albendazole demonstrated a
reduction in seizures and enhanced resolution of cysts after
treatment [95]. Although a landmark study, the treatment
was not completely eﬀective. The number of patients who
became free of seizures was similar in the two groups,
but the reduction in the number of the seizures among
patients who received the treatment was signiﬁcant in
patients with generalized seizures, not in the group with
partial seizures. Further studies are needed to determine
whether longer or repeated courses of therapy will result
in a decrease in seizures overall and leave patients with
fewer remaining cysticerci. A recent meta-analysis conﬁrmed
that treatment of parenchymal NCC is clinically beneﬁcial
[96]. These authors concluded drug therapy results in better
resolution of colloidal and vesicular cysticerci, lower risk for
recurrence of seizures in patients with colloidal cysticerci,
and a reduction in the rate of generalized seizures in patients
with vesicular cysticerci. However, there were not suﬃcient
data to determine conclusively the superiority of either
albendazole or praziquantel as ﬁrst-line treatment of NCC
in this meta-analysis [96]. Despite the numerous studies, an
optimal therapeutic regimen for neurocysticercosis has not
been established. The evidence favors albendazole over praz-
iquantel, but longer courses and repeated courses might be
needed for patients with multiple cysts. Future trials should
look to deﬁne the optimal therapeutic regimen. A recent
prospective, randomized placebo, controlled trial examined
combination therapy with albendazole and praziquantel
versus albendazole alone in 110 children with seizsures and
single enhancing lesions. There were no diﬀerences in recur-
rent seizures and resolution of the lesions. Larger studies are
warranted with combination therapy in both parenchymal
disease and extraparenchymal forms of neurocysticercosis
[97].
Single enhancing lesions have a good prognosis. Studies
examining this groupofpatients haveshownvariableclinical
results, probably due to the heterogeneity of morphology of
single enhancing lesions. The most rigorous double-blinded
randomized treatment trial showed an initial increase in
seizureoccurrence,butinafollow-upevaluationattwoyears
there was a signiﬁcant beneﬁt of treatment [87, 88]. The
previously mentioned meta-analysis found that enhancing
lesions beneﬁted from treatment with antiparasitics [96].
Solid nodular cysts that are degenerating have shown
resolution with antiparasitic treatment. Calciﬁed cysts need
not be treated with antiparasitic agents [4, 71].
Anticonvulsants are should be used to control seizures.
Serum levels of phenytoin and carbamazepine may be
lowered when given concomitantly with praziquantel [98].
There is no proven eﬀective treatment for perilesional
edema associated with calciﬁed lesions. Steroids can control
symptoms, but there are no data that treatment with steroids
will prevent recurrent edema [4, 14]. Methotrexate has
been used in patients with recurrent perilesional edema
to control the host inﬂammatory response as a steroid
sparing agent in patients requiring long-term steroids [99,
100]. Patients with cysticercotic encephalitis should not be
treated with cysticidal drugs because this may exacerbate
the intracranial hypertension. Treatment should be aimed at
relieving edema with corticosteroids (up to 32mg per day of
dexamethasone) and mannitol at doses of 2mg/kg per day
[2].
5.2. Extraparenchymal NCC. There are no controlled trials
on the management of subarachnoid disease. In a series
of patients treated with only CSF diversion, 50% died at a
median follow-up of 8 years and 11 months [101]. Cysticidal
drugs with steroids and shunting for hydrocephalus have
been used with success in subarachnoid disease [46, 102,
103]. The host inﬂammatory reaction around the cysts may6 Interdisciplinary Perspectives on Infectious Diseases
result in occlusion of leptomeningeal vessels resulting in
stroke or hydrocephalus [9, 101]. Therefore, steroids must
be used in conjunction with therapy [2, 4, 55]. Most experts
consider subarachnoid NCC an indication for treatment
with antiparasitic agents [71]. There is no consensus on the
dose of antiparasitic agent or length of treatment for this
form of NCC. A study of 33 patients with giant cysticerci in
the Sylvian ﬁssure treated with albendazole (15mg/kg/d for
4 weeks) found only one single death from aplastic anemia
at 59 months, with patients requiring several courses of
therapy [102]. Therefore, a single course in patients with
subarachnoid disease patients is probably inadequate and
long-term therapy (months) might be required to treat some
patients. Similarly, the optimal dose and duration of steroids
has not been determined. Methotrexate has been used as
a steroid sparing agent in subarachnoid disease in patients
requiring long-term steroids and experiencing intolerable
side eﬀects [99].
Therapy for ventricular disease needs to be individual-
ized. Anthelmintic treatment of the fourth, third, and lateral
ventricle has been reported [41, 104–107]. If hydrocephalus
is present patients, should have a shunt placed prior to
medical therapy [106]. Surgery has been the mainstay in
this form of NCC [39, 108]. There is a growing literature
supporting ﬂexible neuroendoscopy to remove approachable
subarachnoid cysts and cysts lodged in the lateral, third, and
fourth ventricles [109–112]. Cysts that enhance on MRI may
not be suitable for endoscopic removal.
It is important to recognize that the management of
NCC is complicated and involves antiinﬂammatory agents,
antiparasitic drugs, and in some cases surgery. It should be
managed by physicians knowledgeable in this ﬁeld.
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